Of the 212 randomized trials, 97 used activecomparator, and the remainder used an inactive control. Active-comparator trials were less likely to report positive results than a study with inactive control. The authors concluded that only one-third of the studies evaluating medications in key journals were CER studies. Few studies focused on safety or cost, and most were funded by noncommercial funding sources. Authors also concluded that regulatory agencies such as the US Food and Drug Administration (FDA) should require active-comparator studies for drug approval whenever feasible. Most clinicians realize that many treatment decisions are not evidence or CER based. This study demonstrated a current paucity of CER research, particularly relating to safety that could be remedied by government intervention in research focus.
The American Recovery and Reinvestment Act (ARRA) of 2009 provided $1.1 billion for comparative effectiveness research. ARRA provided $300 million for the AHRQ, $400 million for the National Institutes of Health, and $400 million for the Office of the Secretary of Health and Human Services. I have followed this relatively new research approach for a number of years. CER may be completed using gold standard randomized controlled clinical trials but also database analysis, meta-analysis, and various other means. It is not without controversy. 2 Although CER demonstrates a great deal of promise to strengthen the physician-patient relationship, it has its detractors. Some critics claim that government control of CER provides the foundation for rationing. Once ''best practice'' is established, the premise for funding and treatment denial has been established. What will the self-evident and perceived economic nature of CER become in relation to personalized medicine? Will outcome or economic benefits become CER's salient focus?
I do not want to imply that cost-effectiveness analysis studies are not important, especially relating to more recently marketed drugs. The high cost of newer agents may not be offset by gains in quality of life. In a recent health economic analysis, 3 glyburide, exenatide, and sitagliptin were studied in adults aged 25-64 as second-line antidiabetic therapy in type 2 diabetes. The authors found the following: ''Exanatide and sitagliptin conferred 0.09 and 0.12 additional qualityadjusted life years (QALYs), respectively, relative to glyburide as second-line therapy. In base analysis, exenatide was dominated (cost more and provided *Executive Editor, The Formulary, Facts & Comparisons, St. Louis, Missouri.
fewer QALYs than the next most expensive option), and sitagliptin was associated with an incremental cost-effectiveness ratio of $169,572 per QALY saved.'' Authors conclude that gains in quality and/or quantity of life are necessary for these agents to provide economic value to patients and health care systems. If CER does indeed focus on economic benefit, what impact will this have on the Pharmacy & Therapeutics Committee decision-making process? CER offers promise to foster research that may yield benefit if compared to established therapy.
CER may provide a cornerstone for clinical practice guideline development. It will be important for your Pharmacy & Therapeutics Committee to ensure that appropriate methodological transparency and quality be used in CER so that the health and wellbeing of patients is the primary emphasis, not simply as a mechanism for cost reduction or product promotion. Only a modest amount of medication-related CER currently exists; a seasoned, moderated approach to new CER studies is warranted.
